The president having Covid is a unique situation for Cytodyn. The president is going to get the best care possible as a rule, but the drs and experts surrounding him that need to treat this have all been silent and/or un-aware of Leronlimab. For any of them to bring it up would lead to the question why it was not brought up earlier. Steve Hahn at the FDA must be getting daily updates on all Covid related treatments and must be aware of leronlimab. For him to now bring it up would really make him look like he has been holding back with the president with the possible treatments available.

The importance of the readout from the S/C trial could provide a door to let the experts have a good reason not to bring up Leronlimab until now. They can all say they needed more than the moderate trial data for this non-FDA drug to prove itself. The timing of this is really important. We could be completely out of the picture, or be right in the center of it on a presidential level.